PMC9396030_01
Image picture and pathologic images of mesenteric YST. (A) CT scan of mass in the left lower quadrant. (B) Hematoxylin-eosin staining of the mesenteric YST (x200). (C) Immunohistochemical staining of CK was strong positive(x200). (D) Immunohistochemical staining of AFP was strong positive(x200). (E) Immunohistochemical staining of CD117 was weakly positive (x200). (F) Immunohistochemical staining of PALP was weakly positive (x200). (G) Immunohistochemical staining of CDX2 was weakly positive (x200). (H) Immunohistochemical staining of Ki-67 was 50% positive (x200).
fonc-12-928234-g001.jpg
PMC9396030_01_fonc-12-928234-g001.jpg
f1
Computed tomography (CT) scan revealed a soft tissue mass of approximately 143 x 151 x 125 mm in the left lower quadrant with ascites ( Figure 1A ). Her postoperative pathology was YST of mesenteric ( Figure 1B ). The results of immunohistochemistry were as follows: CK (+++), AFP (+++), CD117 (+), PALP (+), CDX2 (+), CD34 (+), EMA (+), CD56 (+), CD20 (+), Ki67 (50% +), and other immune markers were negative ( Figures 1C-G ).
The changing trend of serum alpha-fetoprotein. BEP, bleomycin, etoposide and cisplatin; TP, docetaxel and carboplatin; VIP, ifosfamide, cisplatin and etoposide; RT, radiotherapy; PD-1*, tislelizumab; VTC, vinorelbine tartrate capsules; TIP, paclitaxel, ifosfamide and cisplatin; VEFGi, bevacizumab. *: Tislelizumab is an anti-programmed cell death protein-1 (PD-1) antibody.
fonc-12-928234-g002.jpg
PMC9396030_01_fonc-12-928234-g002.jpg
f2
AFP fluctuation was shown in  Figure 2 . A new lesion appeared by
Chest computed tomography scan. (A) Slight interstitial changes in the lung before BEP  chemotherapy. (B) Slight interstitial changes in the lung after BEP  chemotherapy.
fonc-12-928234-g003.jpg
PMC9396030_01_fonc-12-928234-g003.jpg
f3
CT scans before and after BEP  chemotherapy, there was no significant change in the interstitium of the lung. ( Figure 3 ). Currently, we plan to treat the patient with TP/TE (paclitaxel, cisplatin/paclitaxel, etoposide) chemotherapy every 3 weeks, but she is severely myelosuppression and poorly tolerated.